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ABSTRACT 
Objectives: The diagnostic accuracy of faecal calprotectin (FC) concentration for paediatric 
inflammatory bowel disease (IBD) is well described at the population level, but not at the 
individual level. We reassessed the diagnostic accuracy of FC in children with suspected IBD 
and developed an individual risk prediction rule using individual patient data. 
Methods: MEDLINE, EMBASE, DARE, and MEDION databases were searched to identify 
cohort studies evaluating the diagnostic performance of FC in paediatric patients suspected of 
having IBD. A standard study level meta-analysis was performed. In an individual patient 
data meta-analysis we reanalysed the diagnostic accuracy on a merged patient dataset. Using 
logistic regression analysis we investigated whether and how the FC value and patient 
characteristics influence the diagnostic precision. A prediction rule was derived for use in 
clinical practice and implemented in a spreadsheet calculator. 
Results: According to the study level meta-analysis (9 studies, describing 853 patients), FC 
has a high overall sensitivity of 0.97 (95% confidence interval 0.92 to 0.99) and a specificity 
of 0.70 (0.59 to 0.79) for diagnosing IBD. In the patient level pooled analysis of 742 patients 
from 8 diagnostic accuracy studies, we calculated that at a FC cut-off level of 50 μg/g there 
would be 17 % (95% confidence interval 15 to 20) false positive and 2% (1 to 3) false 
negative results. The final logistic regression model was based on individual data of 545 
patients and included both FC level and age. The area under the ROC curve of this derived 
prediction model was 0.92 (95% confidence interval 0.89 to 0.94). 
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Conclusions: In high prevalence circumstances, FC can be used as a non-invasive biomarker 
of paediatric IBD with only a small risk of missing cases. To quantify the individual patients’ 
risk, we developed a simple prediction model based on FC concentration and age. Although 
the derived prediction rule cannot substitute the clinical diagnostic process it can help in 
selecting patients for endoscopic evaluation.  
 
Key words: inflammatory bowel diseases; leukocyte L1 antigen complex; meta-analysis as 
topic; infant;  child; adolescent  
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Introduction 
As many as 25% of all IBD cases present in childhood. Given the impact of the disease and its 
therapy, a reliable and timely diagnosis is mandatory (1). However, the reference standard, 
endoscopic evaluation with biopsies (2), is invasive, not without risks, and also costly. 
Faecal calprotectin (FC) has been investigated as a surrogate marker of neutrophil influx into 
the bowel lumen and a non-invasive diagnostic test for IBD (3, 4). 
van Rheenen and co-workers (5) published a study-level meta-analysis on the diagnostic 
accuracy of FC for IBD in both children and adults. Based on the calculated summary 
estimates for specificity, sensitivity and likelihood ratios they concluded that the test is a 
useful screening tool for identifying those patients most likely needing endoscopic evaluation. 
A key problem is however that this meta-analysis was based on aggregate data and did not 
account for different cut-off levels or different patient characteristics (6). 
By contrast, individual patient data (IPD) meta-analysis allows using the original test results 
as continuous data rather than as dichotomous classification data. In addition, the effect of 
patient characteristics on test accuracy can be evaluated and quantified (6, 7). 
We undertook the current study to update the study-level meta-analysis on the diagnostic 
performance of FC for paediatric IBD and to complement it with an individual-level meta-
analysis. We also sought to develop a prediction model for IBD based on calprotectin level 
and readily available patient variables.  
 
Materials and Methods 
The research was conducted in accordance with the Code of Conduct for Medical Research of 
the Dutch Federation of Biomedical Scientific Societies (8). 
Identification, selection and appraisal of the relevant studies was carried out independently, by 
two reviewers (PLJD, MPAB). Disagreements were resolved through discussion.  
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Search methods for identification of studies 
A systematic search was performed initially from inception to December 2010 in MEDLINE 
(Ovid), EMBASE (Ovid), the Database of Abstracts of Reviews of Effects (DARE) of the 
Centre for Reviews and Dissemination (9) and the MEDION database of the University of 
Maastricht (10). The electronic search was last updated on April 1, 2012. We refrained from 
using a diagnostic search filter (11, 12) or language restrictions. Details of the search are 
given in an online-only document (eText 1, http://links.lww.com/MPG/A396). Duplicate 
articles identified in both Medline and Embase were manually deleted. The reference lists of 
selected studies were checked for further relevant studies. 
 
Study selection 
Only cohort studies evaluating the diagnostic performance of FC concentration in paediatric 
patients suspected of having IBD were considered for review. Other study designs, such as 
case-control, are indeed prone to spectrum bias (13). In addition, the following inclusion 
criteria were applied: FC measurement and reference standard available for all paediatric 
participants (or a follow-up period long enough to exclude IBD), and sufficient data to 
calculate 2 x 2 tables. 
 
Data abstraction 
The following data were extracted from each study on a pre-designed form: the spectrum of 
the studied population (indication for testing, age and gender), details of the index and 
reference test, and counts in the 2 x 2 table. 
 
Individual patient data sets 
For the IPD meta-analysis, we contacted the authors of the selected studies and invited them 
to share the raw, de-identified study data (FC level, age, sex, and final diagnosis). The raw 
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data were checked for internal consistency against the summary results published in the 
original paper. Some small discrepancies were found, discussed with the authors and 
ascertainable divergences were corrected. 
 
Quality assessment 
The quality of the included studies was assessed using the revised QUADAS tool (14). Since 
the calprotectin assay is an objective measurement, 3 of 14 items were omitted: blinded 
interpretation of the index test, availability of clinical data, and reporting of uninterpretable 
results. Two reviewers independently answered the 11 remaining questions in the affirmative, 
in the negative or as being unclear.   
 
Data synthesis and (statistical) analysis 
Literature-based meta-analysis: 
The aggregate data meta-analysis was performed in Stata/SE version 11.2 (Stata Corporation, 
College Station, TX, USA) using the Midas command (15). Accordingly, summary statistics 
for all diagnostic performance indices were calculated within the bivariate mixed-effects 
logistic regression modelling framework. Between-study heterogeneity of the results was 
assessed graphically by using forest plots of the diagnostic odds ratios, and statistically by 
using the χ2 test of homogeneity and the inconsistency index (I2).(16) An I2 value greater than 
50% was taken to indicate significant heterogeneity. The potential for publication bias was 
estimated by using a Deeks’ funnel plot. As recommended, a p-value < 0.1 was considered 
statistically significant (17). A hierarchical summary receiver operating characteristic graph 
with 95% confidence region and 95% prediction region was constructed. 
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Individual patient-based meta-analysis: 
Although we largely prefer the analytical approach using logistic regression, we also 
evaluated the diagnostic performance of FC based on the merged individual data. The 
diagnostic performance was calculated through the MedCalc software, version 11.5.01. 
(MedCalc Software, Mariakerke, Belgium). 
 
Logistic regression analysis – predicted probability: 
The contribution of calprotectin concentration and age, as continuous variables, and gender 
and study as categorical variables, to the diagnosis of IBD was explored using stepwise 
forward (likelihood ratio) binary logistic regression analysis. The logit and logistic command 
in Stata/SE 10.1 were used. An entry probability for each variable was set at 0.05. A clinical 
prediction rule was derived from the final regression model (see eText 1, 
http://links.lww.com/MPG/A396, for calculation details).  
 
Results 
Description of studies 
Our search (see Figure 1) returned 161 citations. After removal of 36 duplicates and because 
104 of the abstracts were considered not pertinent, 23 records were retrieved as full texts. An 
additional 4 studies were excluded because of the inappropriateness of the population studied. 
Insufficient information was available for constructing a 2-by-2 table from 3 studies. 
Eventually, eight cohort studies fulfilled the inclusion criteria (18-25). A ninth relevant 
population-based cohort study was discovered in a recently published diagnostic meta-
analysis (5). The original study (26) does not provide data to construct a 2x2 table, but the 
meta-analysis does. 
The authors of eight cohort studies (18-25) were willing to share a data set with individual 
patient data (age, gender, calprotectin concentration, and final diagnosis). Age and gender 
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were not available from the Diamanti et al. study due to a computer crash. The authors of the 
Ashorn et al. paper (Dr. Kolho) provided data on 31 additional patients recruited after 
publication of their study results (18). In the most recently published study (25) not all 
patients underwent endoscopy, but a sufficiently extended follow-up period (disease free 
period of 6 months) should minimize the risk of verification bias (27). To completely 
eliminating this type of bias, we excluded the 43 patients without histologically confirmed 
IBD from the IPD meta-analysis. The Norwegian group (26) justified their refusal by arguing 
that the data will again be used for their own follow-up study. None of the authors is aware of 
missed (un)published diagnostic accuracy studies fulfilling the selection criteria. 
 
Characteristics of included and excluded studies  
All nine included cohort studies (18-26) were undertaken in referral centres for paediatric 
gastroenterology and involved 853 patients from the toddler age group to young adults. Table 
1 summarizes the characteristics of the study population, a description of the applied index 
and reference tests, and the findings. In one study (19) four patients were excluded because 
infectious gastroenteritis was the final diagnosis. Upon enquiry, none of the authors were 
aware of similar patients in whom readily available diagnostic investigation could have 
prevented unjustified study entry and unnecessary false positive or true negative cases. 
Another study (24) contained 16 patients whose calprotectin results were expressed as greater 
or less than a numerical value. These test results were substituted by a value midway between 
the reported numerical value and a higher or lower value present in the data set. This 
procedure is unlikely to influence the test accuracy parameters since 14 of the 16 adjusted 
values were situated in the highest or lowest quintile.  The bar graph in eFigure 1 
(http://links.lww.com/MPG/A395) is a representation of the quality of the 9 selected cohort 
studies (18-26). 
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Summary results for all included studies  
Literature-based meta-analysis: 
A summary of test accuracy estimates is shown in Table 2. The Cochran Q test and the I2 
values are indicative for substantial heterogeneity (28). Figure 2 shows a forest plot of the 
diagnostic odds ratio and the pooled estimate for the 9 cohort studies (18-26). The average 
prevalence of IBD in the cohort studies was 0.54. Accordingly, the post-test probability of a 
positive calprotectin test could be estimated to be 0.79 (95% CI 0.72-0.85). The post-test 
probability of a negative calprotectin test is 0.05 (0.01-0.14). 
Figure 3 shows the hierarchical summary receiver operating characteristic (HSROC) graph 
with 95% confidence region and 95% prediction region.   
Publication bias was assessed by Deeks’ funnel plot asymmetry test for small study 
effect/publication bias. The non-significant slope (p=0.62) indicates that no significant bias 
was found. 
 
Individual patient-based meta-analysis:  
Individual patient data on final diagnosis and FC were collated from 742 children from 8 
studies (18-25). The studies were significantly different with respect to age (p=0.004, one-
way ANOVA test), mean FC concentration (p <0.001, one-way ANOVA test), and area under 
the ROC curve (p=0.001, one-way ANOVA). The pre-test probability ranged from 0.51 (95% 
CI 0.39-0.63) to as high as 0.84 (0.75-0.90). 
In the pooled data set of all children the “optimal” cut-off value (the value with the highest 
accuracy – minimal false negative and false positive results) for FC was 212 μg/g 
corresponding with a sensitivity of 0.90 (95% CI 0.87-0.93), a specificity of 0.85 (0.81-0.88), 
a positive likelihood ratio of 5.99 (4.6-7.8), and a negative likelihood ratio of 0.11 (0.09-0.20). 
The area under the receiver operating characteristic (ROC) curve of FC for the diagnosis of 
paediatric IBD was 0.94 (95% CI 0.92-0.95). 
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Logistic regression analysis – predicted probability  
The results of the logistic regression analysis (eText 1, http://links.lww.com/MPG/A396) 
disclosed that calprotectin concentration, age and study centre were independent predictors of 
IBD. The influence of study centre (likelihood ratio test significant) confirms heterogeneity 
across the studies.  
Outside the 8 study centres a regression equation containing a term related to the study centre 
is not of use, therefore the impact of study centre on the diagnosis was omitted from the final 
regression model: logit(p) = S = -3.294 + 0.004 ∗ FC + 0.175 ∗ AGE, where the explanatory 
variable FC is the FC concentration in μg/g and AGE is the age in years. The predictivity of 
this simplified model was evaluated by ROC curve analysis. The estimated area under the 
ROC curve (AUC) for the final model was calculated to be 0.92 (95% CI 0.89-0.94). The 
logistic model using calprotectin concentration and age predicts IBD correctly in 85.5% 
(466/545) of children (sensitivity 0.81 (95% CI 0.76-0.85), specificity 0.92 (0.88-0.95), PPV 
0.93 (0.89-0.96) and NPV 0.73 (0.72-0.83). 
The probability of having IBD is determined by the equation: p = exp(S)/(1+exp(S)). We 
programmed an Excel spreadsheet (eFile1, http://links.lww.com/MPG/A397) computing the 
probability (with CI) of having IBD for each combination of FC, age and disease prevalence. 
Figure 4 illustrates that assuming a disease prevalence of 56%, a FC of 700 μg/g in a 6 year 
old child corresponds to an IBD probability of 64% (95% CI: 52-71). This prediction lacks 
precision and the post-test probability is hardly improved compared to the average pretest-
probability. In a 17 year old adolescent the same test result makes the diagnosis quite 
probable, but ruling out IBD at this age and this pre-test probability is practically impossible.  
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Discussion 
Principal findings 
This systematic review has provided an updated aggregate data meta-analysis confirming the 
high diagnostic accuracy of FC for the detection of IBD in referral centres for paediatric 
gastroenterology. In addition, a meta-analysis using individual participant data enabled us to 
develop an algorithm predicting the likelihood that an individual child suffers from IBD. It 
was previously not recognized that the probability of having IBD depends both on the FC 
level and the age of the child. 
 
General considerations 
The literature-based meta-analysis indeed confirms that FC has an excellent overall sensitivity 
of 0.97 (95% CI 0.92-0.99) and a modest specificity of 0.71 (0.59-0.80) for diagnosing 
paediatric IBD. A first observation is that, due to the relatively small number of pooled 
investigated patients, the imprecision of the predictive values is still considerable. 
In addition, although we used recommended, robust state of the art statistical methodology 
(29), the estimation of summary points does not hold true if the included studies have used 
different threshold values (30). For the clinician, it is not evident at which cut-off value the 
calculated summary estimates of the test accuracy measures apply. Therefore we recalculated 
the diagnostic performance of FC using merged individual patient data. The “optimal” cut-off 
for the whole group equals 212 μg/g. Taking into account the pretest probability and the 
likelihood ratios, the clinician can now better interpret a test result and discuss the predictive 
value with the patient and his/her parents. We should however realize that the predictive 
values or likelihood ratios are applicable to the whole group of patients presenting with a test 
result above or below the threshold and that dichotomizing carries with it a loss of 
information for the individual child (31). This drawback can be overcome by using logistic 
Copyright © ESPGHAN and NASPGHAN. All rights reserved.
regression analysis, a technique which allows taking into consideration patient-level 
covariates as well.  
The contribution of age in the prediction of IBD turned out to be significant. FC 
concentrations have been shown to be higher in preschool children, especially infants, than in 
older children (32, 33). This age-dependency does not seem to play an important role in our 
logistic regression model since there is no significant correlation between age-quartile and FC 
in non-IBD subjects (r = -0.06; p = 0.34). In contrast, the prevalence of IBD is significantly 
increased with higher age-quartile (Chi-square test, p<0.0001), suggesting that the age factor 
corrects for the age dependent prevalence.  
Our literature search revealed some of the well-known shortcomings in the quality and 
reporting of diagnostic research (27). We had to exclude nearly half of the paediatric accuracy 
studies because they used a case-control design known for introducing spectrum bias (13). 
None of the studies pre-specified a target value for sensitivity, specificity, predictive accuracy 
and a minimal acceptable lower confidence limit, enabling sample size calculation (34, 35). 
Admittedly, neither did we define a target region within which the summary estimates of our 
meta-analysis should fall. We suggest that the absence of a predefined target makes authors 
all too often undeservedly enthusiastic about the diagnostic value of an index test. 
Our meta-analysis differs in some aspects from the study of van Rheenen and co-workers (5). 
They included one study which we excluded (36) whereas we added three new studies 
totalling 404 participants (20, 22, 25). Doctor Golden (personal communication – 03-18-2010) 
discouraged us from using her group’s data (36) because Magne Fagerhol's original assay, 
measuring calprotectin as mg/L assay buffer, does not correlate very well with the new 
commercial assays expressing the results as μg/g faeces.  
The major difference between van Rheenen’s (5) and this paper is the IPD meta-analysis. As 
already known, the collection of individual patient data is time consuming and difficult. A 
high level of persuasiveness was needed to collect the raw study data from 8 of the 9 cohort 
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studies. Consequently, we were able to use easily available patient characteristics and the 
original continuous calprotectin data instead of the dichotomized study results in a logistic 
regression analysis.  
It is also noteworthy that we detected and were able to correct small discrepancies between 
the raw data and the published data.   
By publishing all the available raw data (eTable 1, http://links.lww.com/MPG/A398), we 
comply with the appropriate and growing request to share complete data, allowing re-analysis 
by the reader and sequential meta-analysis if new studies appear. There is indeed a growing 
awareness that sharing data is an ethical obligation (37-42). 
 
Strength of the study 
Compared to the systematic review of van Rheenen et al. (5), the key strength of our study is 
the IPD meta-analysis. Although a literature-based meta-analysis provides a good overall 
impression of the diagnostic accuracy of the test, pooling of studies with different diagnostic 
thresholds (from 50 to 160 μg/g faeces) precludes the calculation of the predictive value at a 
self-selected threshold or the patient’s result. Only IPD permits prediction based on numerical 
test results and adjustment for patient characteristics. Our prediction tool calculates an 
individualized disease risk with accompanying confidence range taking into account the FC 
concentration and the patient’s age. In a paediatric gastroenterology referral centre, ruling out 
IBD is difficult in older children, whereas in younger patients a higher FC concentration is 
needed to get a post-test probability larger than the prevalence.  
 
Study weaknesses 
Our search methodology aimed to avoid language and citation bias but we cannot exclude 
publication or reporting bias in our meta-analysis. Publication bias is probably even more of a 
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problem for diagnostic and prognostic than for therapeutic studies (43, 44). The effects of 
reporting bias in therapeutic meta-analyses have recently been shown to be substantial (45). 
Our IPD meta-analysis may also suffer from availability bias. Data from two large studies are 
incomplete or unavailable. In this context, it is noteworthy that the study of Perminow et al. 
(26) was not intended to be a diagnostic accuracy study and showed the lowest diagnostic 
odds ratio.  
We also recognize that the number of patients in the meta-analysis is still limited. Therefore 
the precision of the diagnostic accuracy measures and our predictive algorithm leaves room 
for improvement. Furthermore, the final logistic regression equation contains only two 
independent variables. This likely represents an oversimplification of a complex clinical 
diagnostic process, including information collected during history taking and physical 
examination. The user of the algorithm should be aware of this. Other laboratory test results, 
such as CRP, haemoglobin, and iron indicators, could improve diagnostic precision but were 
not available for this study. Clinical suspicion or “gut feeling” may also be of additional 
diagnostic value.  
Finally, the between-study heterogeneity is of concern and not fully understood. Although the 
selection criteria are more or less the same (suspected inflammatory bowel disease), between-
study differences were shown for age and FC concentration.  The prevalence of IBD varied 
from 51% to 84%, and the false positive rate ranged from 0 to 29% suggesting dissimilar 
study entry criteria. We have also noticed that there was a negative, just significant linear 
correlation (r = -0.71, P=0.049) between prevalence and the false positive rate.  
Differences in clinical laboratory measurement procedures for FC may be another source of 
heterogeneity (46). We know that even small analytic biases can indeed shift the laboratory 
values and lead to diagnostic misclassification (47, 48). 
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Implications for clinical practice and future research 
Despite the absence of validation, and given the mentioned concern about study heterogeneity 
and (reporting) bias, our predictive algorithm is currently the best available tool for predicting 
IBD in the individual child. As such it deserves a valid place in the decision making process.  
We nevertheless advocate a large prospective multi-centre study to improve and refine the 
IBD screening tool. More data are needed to validate the prediction algorithm on a different 
data set to improve its precision. Every effort should be made to standardize and harmonize 
calprotectin measurements and the predictive value of other clinical variables and (faecal) 
biomarkers (49, 50) should be investigated simultaneously.  
 
Conclusion 
Using an IPD meta-analysis and through regression modelling we identified FC concentration 
and age as independently associated with the diagnosis of IBD. We developed a prediction 
rule that enables the practicing paediatric gastroenterologist to numerically interpret the FC 
value together with the patient’s age. As such, this rule can be a valuable adjunct to the 
diagnostic armamentarium making physician and patients/families better equipped to make 
personalized decisions.  
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Figure, Table Legends and Supplemental Data 
Figure 1. Flowchart showing the search for and selection of papers evaluating faecal 
calprotectin in children with suspected inflammatory bowel disease. The final search was 
carried out on April 1st, 2012 
 
Figure 2. Forrest plot of diagnostic odds ratio of each individual cohort study, pooled odds 
ratio, Cochran Q test heterogeneity and I2 statistic for inconsistency. 
 
Figure 3. Summary ROC space of sensitivity and specificity for faecal calprotectin in the 
diagnosis of paediatric IBD. The circles depict the observed bivariate pairs of sensitivity and 
specificity of the 9 diagnostic cohort studies (18-26). The blue solid line is the summary ROC 
curve. The diamond is the bivariate summary point. The red dashed line triangle is the 
bivariate boundary of the 95% confidence region for the bivariate summary point and the 
green dotted line encloses the 95% prediction region. The study numbers correspond to those 
reported in Table 1.  
 
Figure 4. Plots of the predicted probabilities as a function of faecal calprotectin 
concentration, age and disease prevalence. This figure illustrates that age has an important 
additional value to calprotectin testing for the diagnosis of IBD. UL: upper limit of 95% CI, 
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Table 1. Characteristics and 2 x 2 data of all included studies. TP: true positive, FP: false 
positive, FN: false negative, TN: true negative 
 
Table 2. Numerical results of the literature-based meta-analysis (faecal calprotectin for the 
diagnosis of IBD): test performance parameters and their 95% CI. DOR: diagnostic odds 
ratio, LR+: likelihood ratio of a positive test, LR-: likelihood ratio of a negative test. 
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Table 1. Characteristics and 2 x 2 data of all included studies 
Study, year 
(reference) 
Patient characteristics Index test  Cut-off 
value 
(µg/g) 
Reference test Prev TP FP FN TN 








University of Helsinki, 
Finland 
Suspicion of IBD 5.8-19.9 50 Phical Test 100 Histopathology 0.80 39 1 5 10 





enterology Unit; Naples, 
Italy 
Children referred for 

























enterology and Nutrition 
Unit, Rome, Italy 
Children referred for 
recurrent abdominal 




88/109 Calprest®  100 Histological 
examination 
0.59 117 26 0 54 










colonoscopy to rule out 




19/17 Calprest® 50 Conventional 
histopathological 
criteria for diagnosis 
of IBD 








Children evaluated for 
suspected bowel 
inflammation 
IBD 12.6, IQR: 9.5-
14.0 
Non-IBD 9.3, IQR: 
5.2-12.7 
79/111 PhiCal Test 50 Complete 
endoscopic 
evaluation + 
biopsies,  small 
bowel imaging  plus 
follow-up of ≥ 12 
months 
0.48 89 55 2 44 
6 Kolho et 
al, 200625 
Children´s Hospital, 






29/28 Phical Test 50 Colonoscopy + 
histology 
0.54 28 10 3 16 











? 160 Histopathological 
(Porto criteria) 
0.63 54 14 6 21 




































verification or 6 
months follow-up 
0.36 42 20 0 55 
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Table 2. Numerical results of the literature-based meta-analysis (faecal calprotectin for the 
diagnosis of IBD): test performance parameters and their 95% CI along with Cochran-Q and 
inconsistency. DOR: diagnostic odds ratio, LR+: likelihood ratio of a positive test, LR-: 
likelihood ratio of a negative test. 
 
 
Parameter Estimate (95% CI) Cochran-Q (P-value) Inconsistency (I2) (%) (95% CI) 
Sensitivity  0.97 (0.92 to 0.99)   30.21 0.00 73.52 (55.84 to 91.20) 
Specificity  0.70 (0.59 to 0.79)   34.33 0.00 76.70 (61.62 to 91.77) 
DOR     86 (   25 to  300) 1133.20  0.00 99.29 (99.14 to 99.45) 
LR+    3.2 (  2.3 to   4.5)   39.24 0.00 66.87 (66.87 to 92.36)  
LR-  0.04 (0.01 to 0.12)   21.09 0.01 62.06 (34.57 to 89.56) 
 
